Discussion of Bleomycin toxicity
- Bleomycin is commonly used, either alone or in combination with other chemotherapeutic agents, in the treatment of squamous cell carcinomas (of the head and neck, cervix, and vagina), testicular carcinomas, and Hodgkin lymphoma.
- Bleomycin-induced lung injury usually occurs in 3%–5% of treated patients, although there is a marked increased risk if the total cumulative dose is more than 450 units.
- The risk of developing lung injury is increased in the elderly and in patients receiving oxygen therapy, with a history of prior thoracic irradiation, or in whom therapy is reinstituted within 6 months of discontinuation.
- The prognosis is poor, with most patients dying of respiratory failure within 3 months of onset of symptoms.
 Imaging Findings for Bleomycin toxicity
- Diffuse alveolar damage is the most common manifestation of bleomycin-induced lung disease, with nonspecific interstitial pneumonia and cryptogenic organizing pneumonia being less common.
 See Also
 External Links
 References for Bleomycin toxicity
- Santiago E. Rossi, Jeremy J. Erasmus, H. Page McAdams, Thomas A. Sporn, and Philip C. Goodman. Pulmonary Drug Toxicity: Radiologic and Pathologic Manifestations. RadioGraphics 2000 20: 1245-1259.